Although the PPARα‐catalase pathway has been reported in the treatment of alcoholic liver disease,[55] hepatic fibrosis,[56] and skin aging,[57] this study is the first to elucidate its role in mitigating FC‐induced oxidative stress in NAFLD through DhT treatment. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.